Worth reading
60In focus
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
38829
Millions of yenWording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedIFRSNet Sales509,593Millions of yenYear on year +12.2%
Operating profit84,962Millions of yenYear on year +84.2%
Ordinary income82,607¥ million (profit before tax)Year on year +84.5%
Net income attributable to owners of the parent52,146¥ million (interim profit attributable to owners of the parent)Year on year +78.7%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
Net income per share¥48.78
Financial position at period-end
Total assets1,521,887Millions of yen
of which net assets 755,407 Millions of yenEquity ratio 49.6%vs. prior year-end -3.2pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+62,329
Investment-84,239
Financials-7,942
Net change-29,852
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period157,736 Millions of yen
Segment revenueGastrointestinal Endoscopy Solutions 352,982 Millions of yen (YoY +15.0%), Surgical Intervention 156,560 Millions of yen (YoY +6.4%)
Segment profitGastrointestinal Endoscopy Solutions ¥98,784 million (operating profit) (YoY +84.8%), Surgical Intervention ¥3,159 million (operating profit)
Regional salesRegion Japan / Current interim period 48,542 Millions of yen / Previous interim period 49,015 Millions of yen, Region North America / Current interim period 214,724 Millions of yen / Previous interim period 182,464 Millions of yen, Region Europe / Current interim period 135,886 Millions of yen / Previous interim period 119,094 Millions of yen, Region China / Current interim period 38,623 Millions of yen / Previous interim period 37,589 Millions of yen, Region Asia and Oceania / Current interim period 53,587 Millions of yen / Previous interim period 49,455 Millions of yen, Region Other / Current interim period 18,231 Millions of yen / Previous interim period 16,733 Millions of yen
Outlook and shareholder returns
Full-year earnings forecast
Net SalesLimit 1,076,000 Millions of yen / Downside floor 1,064,500 Millions of yen / Change from previous period Limit 6.5 / Downside floor 5.3
Operating profitLimit 167,500 Millions of yen / Downside floor 155,000 Millions of yen / Change from previous period Limit 72.5 / Downside floor 59.6
Ordinary incomeLimit ¥162,500 million (profit before tax) / Downside floor ¥150,000 million (profit before tax) / Change from previous period Limit 72.9 / Downside floor 59.6
Net incomeLimit ¥112,000 million (profit attributable to owners of the parent) / Downside floor ¥103,500 million (profit attributable to owners of the parent) / Change from previous period Limit 64.3 / Downside floor 51.8
Revision to Earnings ForecastNet Sales 1,076,000～1,055,000 / Operating profit 155,500～136,500 / Pretax profit 149,500～130,500 / Profit for the year attributable to owners of the parent 109,000～95,500 → Net Sales 1,076,000～1,064,500 / Operating profit 167,500～155,000 / Pretax profit 162,500～150,000 / Profit for the year attributable to owners of the parent 112,000～103,500（Net Sales 0.0～0.9% / Operating profit 7.7～13.6% / Pretax profit 8.7～14.9% / Profit for the year attributable to owners of the parent 2.7～8.4%）
Annual Dividend Forecast30 Yen → 30 Yen（0.0%）
Factors Behind Changes in Business Performance
Operating profit increased due to higher revenue from both businesses, the foreign-exchange impact of the weaker yen, refunds of US tariffs, and the absence of one-off costs such as quality assurance and regulatory compliance costs recorded in the same period of the previous year. At the same time, the company recorded organizational change and workforce optimization costs, business restructuring-related costs, impairment losses and other expenses.
Disclosure regarding the going concern assumption
No matters to report
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 1 / Company name BioProtect Ltd. / Excluded Number of companies 0 / Company name Not disclosed
Impairment loss1,095 Millions of yen
Depreciation and amortization35,453 Millions of yen
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Analysts and institutional investors
Issued Shares at Period-End1,114,485,700
Treasury Shares at Period-End51,633,155
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | 509,593 Millions of yen (YoY +12.2%) |
| Operating profit | 84,962 Millions of yen (YoY +84.2%) |
| Ordinary income | ¥82,607 million (profit before tax) (YoY +84.5%) |
| Profit attributable to owners of the parent | ¥52,146 million (interim profit attributable to owners of the parent) (YoY +78.7%) |
| Net income per share | ¥48.78 |
| Equity ratio | End of the current fiscal period 49.6 / End of previous period 52.8 |
| Total assets | 1,521,887 Millions of yen |
| Net assets | ¥755,407 million (total equity) |
| Cash flows from operating activities | 62,329 Millions of yen |
| Cash flows from investing activities | -84,239 Millions of yen |
| Cash flows from financing activities | -7,942 Millions of yen |
| Cash and cash equivalents at end of period | 157,736 Millions of yen |
| Full-year earnings forecast | Net Sales Limit 1,076,000 Millions of yen / Downside floor 1,064,500 Millions of yen / Change from previous period Limit 6.5 / Downside floor 5.3 / Operating profit Limit 167,500 Millions of yen / Downside floor 155,000 Millions of yen / Change from previous period Limit 72.5 / Downside floor 59.6 / Ordinary income Limit ¥162,500 million (profit before tax) / Downside floor ¥150,000 million (profit before tax) / Change from previous period Limit 72.9 / Downside floor 59.6 / Net income Limit ¥112,000 million (profit attributable to owners of the parent) / Downside floor ¥103,500 million (profit attributable to owners of the parent) / Change from previous period Limit 64.3 / Downside floor 51.8 |
| Revision to Earnings Forecast | Net Sales 1,076,000～1,055,000 / Operating profit 155,500～136,500 / Pretax profit 149,500～130,500 / Profit for the year attributable to owners of the parent 109,000～95,500 → Net Sales 1,076,000～1,064,500 / Operating profit 167,500～155,000 / Pretax profit 162,500～150,000 / Profit for the year attributable to owners of the parent 112,000～103,500（Net Sales 0.0～0.9% / Operating profit 7.7～13.6% / Pretax profit 8.7～14.9% / Profit for the year attributable to owners of the parent 2.7～8.4%） |
| Annual Dividend Forecast | 30 Yen → 30 Yen（0.0%） |
| Segment revenue | Gastrointestinal Endoscopy Solutions 352,982 Millions of yen (YoY +15.0%), Surgical Intervention 156,560 Millions of yen (YoY +6.4%) |
| Segment profit | Gastrointestinal Endoscopy Solutions ¥98,784 million (operating profit) (YoY +84.8%), Surgical Intervention ¥3,159 million (operating profit) |
| Regional sales | Region Japan / Current interim period 48,542 Millions of yen / Previous interim period 49,015 Millions of yen, Region North America / Current interim period 214,724 Millions of yen / Previous interim period 182,464 Millions of yen, Region Europe / Current interim period 135,886 Millions of yen / Previous interim period 119,094 Millions of yen, Region China / Current interim period 38,623 Millions of yen / Previous interim period 37,589 Millions of yen, Region Asia and Oceania / Current interim period 53,587 Millions of yen / Previous interim period 49,455 Millions of yen, Region Other / Current interim period 18,231 Millions of yen / Previous interim period 16,733 Millions of yen |
| Depreciation and amortization | 35,453 Millions of yen |
| Impairment loss | 1,095 Millions of yen |
| Disclosure regarding the going concern assumption | No matters to report |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 1 / Company name BioProtect Ltd. / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Analysts and institutional investors |
| Issued Shares at Period-End | 1,114,485,700 |
| Treasury Shares at Period-End | 51,633,155 |
| Factors Behind Changes in Business Performance | Operating profit increased due to higher revenue from both businesses, the foreign-exchange impact of the weaker yen, refunds of US tariffs, and the absence of one-off costs such as quality assurance and regulatory compliance costs recorded in the same period of the previous year. At the same time, the company recorded organizational change and workforce optimization costs, business restructuring-related costs, impairment losses and other expenses. |
Items this document does not state (6)
Operating MarginPayout ratioShareholder Return PolicyOrders received and order backlogBreakdown of extraordinary income (loss)Material subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Profit increased due to higher revenue from the Digestive Endoscopy Solutions and Surgical Intervention businesses, the foreign-exchange benefit from the weaker yen, refunds of US tariffs, and the absence of one-off costs recorded in the same period of the previous year. The full-year forecast was revised to reflect progress through the second quarter and the outlook for the remainder of the year, as well as to incorporate refunds of US tariffs.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.